ABSTRACT Objective: The current Centers for Disease Control and Prevention (CDC) guidelines include 2 drugs, doxycycline and ofloxacin, for treatment of the chlamydial component of outpatient pelvic inflammatory disease (PID). Although ofloxacin costs about $90 more than doxycycline, doxycycline is frequently associated with side effects and patient compliance with this drug is probably poor.
that are often delayed, in the form of chronic pelvic pain, infertility, and ectopic pregnancy; these components add an additional annual cost of $3.8 Changing the baseline compliance with doxycycline had no impact on our findings if the relationship between partial compliance and cure were linear (assumption A, Fig. 1 ). However, increasing the baseline compliance level by 20 percentage points increased the break-even point (assumptions B and C, Fig. 1 Fig. 1 ) or "S"-shaped (assumption B, Fig. 1) , with an initially low cure rate that increases rapidly over a short period and levels off after a certain threshold of compliance has been attained.
Or, cure may be achieved rapidly with a relatively low level of compliance (the logistic curve, assumption C, Fig. 1 
